{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:26:01Z","timestamp":1791645961030,"version":"4.3.4"},"reference-count":22,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2022,7,5]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although the initial use of combination treatment has been proven to be beneficial for patients\u2019 clinical outcomes, there are scarce data on its haemodynamic effects. The objective of the present study was to evaluate the effect of an initial combination of pulmonary arterial hypertension (PAH)-targeted therapies on haemodynamic parameters in treatment-na\u00efve PAH patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of PubMed, Cochrane Central Register of Controlled Trials and Web of Science was performed. We considered eligible studies with an intervention of initial PAH-targeted combination therapy in treatment-na\u00efve PAH patients with or without monotherapy control. A random-effects meta-analysis was performed for the difference between baseline and follow-up in pulmonary vascular resistance (PVR) and other haemodynamic parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 880 patients receiving initial combination therapy PVR was reduced by \u22126.5\u2005Wood Units (95% CI \u22127.4\u2013\u22125.7 Wood Units) or by \u221252% (95% CI \u221256%\u2013\u221248%, I<jats:sup>2<\/jats:sup>=0%) compared to baseline. Initial triple therapy including a parenteral prostanoid resulted in significantly greater PVR reduction (\u221267%<jats:italic>versus<\/jats:italic>\u221250% with all other combination therapies, p=0.01). The effect was more pronounced in younger patients (p=0.02). Compared to baseline, there was \u221212.2\u2005mmHg (95% CI \u221214.0\u2013\u221210.4 mmHg) decrease in mean pulmonary artery pressure, 0.9\u2005L\u00b7min<jats:sup>\u22121<\/jats:sup>\u00b7m<jats:sup>\u22122<\/jats:sup>(95% CI 0.8\u20131.1 L\u00b7min<jats:sup>\u22121<\/jats:sup>\u00b7m<jats:sup>\u22122<\/jats:sup>) increase in cardiac index, \u22123.2\u2005mmHg (95% CI \u22124.1\u2013\u22122.3 mmHg) decrease in right atrial pressure and 8.6% (95% CI 6.9\u201310.3%) increase in mixed venous oxygen saturation. In the controlled studies, initial combination therapy reduced PVR by \u22124.2 Wood Units (95% CI \u22126.1\u2013\u22122.4 Wood Units) compared to monotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Initial combination therapy leads to remarkable haemodynamic amelioration. Parenteral prostanoids should be considered early, especially in more severely affected patients, to enable right ventricular reverse remodelling.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00313-2022","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T15:36:26Z","timestamp":1660232186000},"page":"00313-2022","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Haemodynamic effects of initial combination therapy in pulmonary arterial hypertension: a systematic review and meta-analysis"],"prefix":"10.1183","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0586-6386","authenticated-orcid":false,"given":"Ioannis T.","family":"Farmakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-8352","authenticated-orcid":false,"given":"Sophia-Anastasia","family":"Mouratoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanos","family":"Zafeiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Zanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-6319","authenticated-orcid":false,"given":"George","family":"Giannakoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"2024101711384757000_8.4.00313-2022.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01899-2018"},{"key":"2024101711384757000_8.4.00313-2022.2","first-page":"1801913","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"53","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2024101711384757000_8.4.00313-2022.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"2024101711384757000_8.4.00313-2022.4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2024101711384757000_8.4.00313-2022.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"2024101711384757000_8.4.00313-2022.6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.healun.2017.08.009","article-title":"Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension","volume":"37","author":"Badagliacca","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2024101711384757000_8.4.00313-2022.7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/rccm.202004-1006OC","article-title":"Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension","volume":"203","author":"Badagliacca","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711384757000_8.4.00313-2022.8","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024101711384757000_8.4.00313-2022.9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.chest.2019.09.009","article-title":"Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension","volume":"157","author":"D'Alto","year":"2020","journal-title":"Chest"},{"key":"2024101711384757000_8.4.00313-2022.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1398OC"},{"key":"2024101711384757000_8.4.00313-2022.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2011.11.002"},{"key":"2024101711384757000_8.4.00313-2022.12","doi-asserted-by":"crossref","first-page":"P6241","DOI":"10.1093\/eurheartj\/ehy566.P6341","article-title":"Haemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension","volume":"39","author":"Rinaldi","year":"2018","journal-title":"Eur Heart J"},{"key":"2024101711384757000_8.4.00313-2022.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00116313"},{"key":"2024101711384757000_8.4.00313-2022.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02043-2015"},{"key":"2024101711384757000_8.4.00313-2022.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00673-2020"},{"key":"2024101711384757000_8.4.00313-2022.16","doi-asserted-by":"crossref","first-page":"2045894019826944","DOI":"10.1177\/2045894019826944","article-title":"Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension","volume":"9","author":"Sulica","year":"2019","journal-title":"Pulm Circ"},{"key":"2024101711384757000_8.4.00313-2022.17","doi-asserted-by":"crossref","first-page":"170007","DOI":"10.1183\/13993003.00007-2017","article-title":"Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension","volume":"49","author":"van de Veerdonk","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101711384757000_8.4.00313-2022.18","first-page":"474","article-title":"[Effects of iloprost combined with low dose tadalafil in adult congenital heart disease patients with severe pulmonary arterial hypertension: a single-center, open-label controlled study]","volume":"42","author":"Zhang","year":"2014","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"2024101711384757000_8.4.00313-2022.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.12.076"},{"key":"2024101711384757000_8.4.00313-2022.20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711384757000_8.4.00313-2022.21","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.chest.2019.07.005","article-title":"POINT: should initial combination therapy be the standard of care in pulmonary arterial hypertension? Yes","volume":"156","author":"Humbert","year":"2019","journal-title":"Chest"},{"key":"2024101711384757000_8.4.00313-2022.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.068"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00313-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:20:33Z","timestamp":1740374433000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00313-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,24]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1183\/23120541.00313-2022"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00313-2022","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]}}}